Christine Fox to head Teva’s U.S. commercial business

Teva is welcoming a new leader to its team. 

Christine (Chris) Fox, who most recently served as global president of gene therapies at Novartis, will be the new head of Teva’s U.S. commercial business.

Sven Dethlefs, executive vice president, North America commercial, will leave Teva on Nov. 17, 2023.

“On behalf of the Teva board of directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company,” said Richard Francis, Teva’s president and CEO. “I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a heralded pharmaceutical executive with extensive experience growing and overseeing complex business units and regional operations throughout the world. I have every confidence that Chris will bring great strength to Teva and be pivotal to our success.”

[Read more: Teva, Alvotech expand biosimilars partnership agreement]

Fox comes to Teva from her role at Novartis Gene Therapies where she started as president in December 2021. Prior to this role, Fox was vice president and general manager for the Bone, Cardiometabolic and Nephrology business for Amgen. She also served as the general manager of the company’s United Kingdom and Ireland affiliate. Earlier in her career, she also held leadership positions at Merck, Takeda and several startups.

[Read more: Teva rolls out generic Nexavar tablets]

Fox brings more than 30 years of healthcare industry experience with leadership roles in sales, marketing and commercial operations, responsible for teams ranging from 2500+ associates to small, nimble consulting teams. She has a deep understanding of issues affecting the pharmaceutical and biotech sectors, as well as expertise across a range of therapy areas, the company said.